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INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for 80–90% of pri-
mary liver cancers. Worldwide, it is the fifth most common 
cancer and the third most common cause of cancer-related 
death.1 With no specific treatment, the prognosis is very poor, 
and the median survival for patients with early and advanced 
tumors is 6–9 months and 1–2 months, respectively.2,3 Several 
treatment options based on clinical guidelines are available, in-
cluding surgical resection, percutaneous and transarterial in-
terventions, systemic chemotherapy, liver transplantation (LT), 
and radiotherapy (RT). 
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Stereotactic body radiotherapy (SBRT) is a form of radiotherapy that delivers high doses of irradiation with high precision in a 
small number of fractions. However, it has not frequently been performed for the liver due to the risk of radiation-induced liver 
toxicity. Furthermore, liver SBRT is cumbersome because it requires accurate patient repositioning, target localization, control of 
breathing-related motion, and confers a toxicity risk to the small bowel. Recently, with the advancement of modern technologies 
including intensity-modulated RT and image-guided RT, SBRT has been shown to significantly improve local control and survival 
outcomes for hepatocellular carcinoma (HCC), specifically those unfit for other local therapies. While it can be used as a stand-
alone treatment for those patients, it can also be applied either as an alternative or as an adjunct to other HCC therapies (e.g., 
transarterial chemoembolization, and radiofrequency ablation). SBRT might be an effective and safe bridging therapy for pa-
tients awaiting liver transplantation. Furthermore, in recent studies, SBRT has been shown to have a potential role as an immuno-
stimulator, supporting the novel combination strategy of immunoradiotherapy for HCC. In this review, the role of SBRT with 
some technical issues is discussed. In addition, future implications of SBRT as an immunostimulator are considered.
Key Words:  Hepatocellular carcinoma, liver tumors, radiotherapy, stereotactic body radiotherapy, intensity-modulated radio-
therapy, immunotherapy
Review Article
pISSN: 0513-5796 · eISSN: 1976-2437
Yonsei Med J 2018 Oct;59(8):912-922
https://doi.org/10.3349/ymj.2018.59.8.912
Previously, the role of RT for HCC has been questioned due 
to the relatively low radiation tolerance of the liver. However, 
with increasing clinical use and experiences, RT can be con-
sidered an effective and safe local therapy for HCC. Moreover, 
the recent development of modern RT technologies, includ-
ing image-guided RT (IGRT), intensity-modulated RT (IMRT), 
and stereotactic body RT (SBRT), has expanded the indica-
tions of RT. Compared to three-dimensional conformal RT 
(3D-CRT), advantages of IMRT include inverse treatment 
planning method and possible use of many treatment fields, 
which provide high precision and good conformal dose distri-
bution. Specifically, SBRT can be a useful locoregional treat-
ment option for selected patients who are ineligible for trans-
arterial chemoembolization (TACE) or radiofrequency 
ablation (RFA) and who have unresectable, small hepatic le-
sions. Furthermore, SBRT precisely delivers higher ablative 
doses of irradiation in smaller volumes, providing excellent 
local control (LC) with potential survival benefits in HCC.
In this review, we will discuss the current role of SBRT for 
HCC as well as future implications of its use as an immunos-
timulator.
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THE PRINCIPLE OF STEREOTACTIC BODY 
RADIOTHERAPY 
SBRT uses stereotactic non-coplanar conformal RT intended 
for a small number (usually 1–5 fractions) of significantly larg-
er fraction sizes (usually 8–12 Gy/fraction) while limiting the 
dose to adjacent normal tissues.4 The sophisticated and steep 
dose gradient within the target volume usually leads to excel-
lent conformity with steep dose fall-off and high dose delivery 
to the target volume. Since its development to treat intracra-
nial malignancies, SBRT has been extended to treat a wide va-
riety of extracranial tumors. SBRT for liver tumors was first in-
troduced in the 1990s5; however, it has not frequently been 
performed because of the risk of radiation-induced liver dis-
ease (RILD). Furthermore, liver SBRT is cumbersome because 
it requires accurate target localization, patient repositioning, 
control of breathing-related movement, and confers a toxicity 
risk to the adjacent small bowels.
Over the years, many retrospective studies have been per-
formed with larger cohorts, and several phase I/II trials that 
enrolled patients who were ineligible for other local therapies 
have been conducted. Based on the vast body of evidence ac-
cumulated as a result of these studies and trials, the recent 
National Comprehensive Cancer Network guidelines intro-
duced SBRT as an option only in inoperable, ineligible for 
transplant tumors (category 2B).6 However, currently, tech-
nological advances have made it possible for radiation to be 
precisely delivered to small liver tumors, while further reduc-
ing the risk of RILD. The role of SBRT for HCC should be re-
evaluated further with those recent advances in mind, as 
previous phase III trials lacked comparisons with other local 
therapies.
Patient selection
In the currently used guidelines,6-9 the recommended applica-
tions of RT vary (Table 1). Although there is no specific recom-
mendation for SBRT, several guidelines indicate external 
beam RT (EBRT) as an alternative option for single HCC with-
out vascular invasion. Careful patient selection is required for 
SBRT in HCC. Although there is no definite limit to the size or 
number of tumors that can be treated with SBRT, most groups 
included patients with a maximum lesion size of ≤5 cm, al-
though some included patients with tumors up to 10 cm.10,11 
Regarding the number of lesions, patients with 1–3 tumors 
were usually treated, but again no cut-off value has been es-
tablished. The number and size of tumors that can be consid-
ered for SBRT are dependent on the non-tumoral liver volume 
that can be spared (usually 700 cm3). SBRT is also feasible for 
some lesions that are ineligible for surgery or percutaneous 
ablation. These unique cases require clinical consideration. 
RFA is not indicated for tumors in the liver dome, given the 
difficulty of sono-guided tumor targeting under a poor sono-
graphic visual field. Post-RFA failures are also frequent in the 
S1 region, especially the porta hepatis, because of the high 
risk of complications or multivascular tumor supply. Similar-
ly, patients who are eligible for SBRT usually have a central le-
sion of the liver dome, with direct invasion into the vessels, 
and/or with an insufficient outcome from other local thera-
pies, including RFA and TACE (Fig. 1). Regarding liver func-
tion, Child-Pugh class A or upper B are considered appropri-
ate for SBRT, similar to the general guidelines of conventional 
RT for HCC. Dose modifications and strict dose constraint ad-
herence would be required for tumors with Child-Pugh class 
B status.12 The safety of liver radiation for HCC in patients with 
Child-Pugh class C cirrhosis has not been established, as it is 
Table 1. Comparison of Treatment Guidelines for Stereotactic Body Radiotherapy-Eligible Hepatocellular Carcinoma
Guidelines
BCLC NCCN APPLE KLSCG-NCC
Single, ≤2 cm, without VI Subgroup Very early Resectable or transplantable Very early mUICC Stage I 
Primary or  
preferred option
Resection (or LT/RFA/
PEI, if portal pressure/
bilirubin increased)
Resection or LT
Resection (or LT/RFA/PEI, if 
portal pressure/bilirubin 
increased)
Resection or RFA
Alternative  
option
(-)
Locoregional treatment 
(Ablation, arterial directed 
therapies, EBRT)
EBRT TACE, PEI, or EBRT
Single, >2 cm, without VI Subgroup Early Resectable or transplantable Early mUICC Stage II 
Primary or  
preferred option
LT or RFA/PEI Resection or LT LT or RFA/PEI Resection or RFA
Alternative  
option
(-)
Locoregional treatment 
(Ablation, arterial directed 
therapies, EBRT)
SABR, hypofractionated RT TACE, LT, or EBRT
BCLC, Barcelona clinic liver cancer; NCCN, National Comprehensive Cancer Network; APPLE, Asia Pacific Primary Liver Cancer Expert Meeting; KLCSG-NCC, Ko-
rean Liver Cancer Study Group and the National Cancer Center; VI, vascular invasion; LT, liver transplantation; RFA, radiofrequency ablation; PEI, percutaneous 
ethanol injection; EBRT, external-beam radiotherapy; mUICC, modified Union for International Cancer Control; TACE, transarterial chemoembolization; RT, radio-
therapy; SABR, stereotactic ablative radiotherapy.
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are more prone to liver toxicity after SBRT, in part because of 
underlying liver disease and comorbidities.17 In some studies, 
an increasing Child-Pugh score, a measure of liver toxicity 
correlating with overall survival (OS), occurred in 10% and 
30% of patients with early- and advanced-stage HCC within 3 
months after SBRT, respectively.14,18 However, there is a pauci-
ty of data correlating the incidence of liver toxicity with SBRT 
dosimetric parameters for HCC. One Canadian group report-
ed the risk factors associated with a decline in liver function 
after 6-fraction SBRT for HCC.19 Liver toxicity was defined as 
an increase in Child-Pugh score (≥2) 3 months after SBRT. 
Baseline Child-Pugh scores (5 vs. 6) and higher liver doses 
(e.g., mean dose, effective volume, and doses to 700–900 cc) 
were strongly associated with liver function decline 3 months 
after SBRT. A lower baseline platelet count and portal vein 
thrombus were also associated with an increased risk.
unlikely that clinical trials are available for Child-Pugh class C 
patients.13,14 
Liver toxicity after SBRT
The probability of RILD can increase when the radiation dose 
to the whole liver exceeds 35 Gy. Owing to advances in tech-
nology, partial liver irradiation has been successful in reduc-
ing the risk of RILD. According to Dawson and Ten Haken’s15 
review, if the effective liver volume irradiated is less than 25%, 
very high RT doses (higher than 100 Gy) may be delivered 
with low risk of liver toxicity, as long as the liver function is 
proper. Therefore, SBRT to irradiate only a small volume of the 
liver can be performed safely for liver tumors. The most com-
mon SBRT fractionation schemes for HCC according to the 
current literature include 3 fractions×10–20 Gy/fx, 4–6 frac-
tions×8–10 Gy/fx, and 10 fractions×5–5.5 Gy/fx.16 Compared 
with patients with liver metastases, however, those with HCC 
Fig. 1. CT scans of patient cases showing objective responses to SBRT of 60 Gy in 4 fractions for HCC. (A) Before SBRT, the CT scan showed a 3 cm-sized 
viable HCC after multiple TACE treatments at the dome of the liver (white arrows) (AFP/PIVKA-II: 1017 ng/mL/95 mAU/mL). (B) After SBRT, the 1-year post-
SBRT CT scan showed radiologic CR with significantly decreased tumor markers approximating normal levels (AFP/PIVKA-II: 2.04 ng/mL /14 mAU/mL). (C) 
Before SBRT, a 4 cm-sized HCC was observed in the left lobe (white arrows) (AFP/PIVKA-II: 6.14 ng/mL/31 mAU/mL). (D) After SBRT, the 4-month post-
SBRT CT scan showed radiologic CR with further reduced tumor marker levels (AFP/PIVKA-II: 3.38 ng/mL/31 mAU/mL). SBRT, stereotactic-body radio-
therapy; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K ab-
sence or antagonist-II; CR, complete response.
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Respiration control
A critical issue in RT for HCC is the control of respiratory 
movement, as the liver moves over a considerable range dur-
ing respiration. Several ways may be used to treat a moving 
tumor to ensure it receives the intended dose while reducing 
the dose to surrounding normal tissue: motion-encompassing 
four-dimensional CT (4D-CT) images, breath-hold, forced 
shallow breathing, respiratory gating, and real-time tumor 
tracking (Fig. 2). For SBRT, control of respiratory motion 
should be considered more strictly than for conventional RT. 
When performing SBRT, many institutions use not only 4D-
CT images but also other respiratory control methods. Specifi-
cally, real-time tumor tracking using the surrogate on the 
body surface or an internal fiducial marker has demonstrated 
high accuracy. Internal fiducial markers can be residual radio-
opaque lipiodol after TACE or a commercial fiducial marker 
which is inserted under sono-guidance. 
Target delineation and dose constraints
Liver SBRT can be performed with various planning machines 
(e.g., step-and-shoot IMRT, volumetric-modulated arc thera-
py, tomotherapy, and cyberknife). Several target volumes that 
are carefully contoured by a professional radiation oncologist 
are required for SBRT. Gross tumor volume (GTV) is defined 
as a primary tumor plus an abnormal portal area as indicated 
by magnetic resonance imaging (MRI). For patients whose le-
sions are not easily detected by CT, incorporation of MRI in 
planning may also be necessary for more precise target delin-
eation. The deformable image registration method could be 
also usefully utilized.20 Clinical target volume (CTV) is defined 
as GTV plus a 0.3–0.5 cm margin for subclinical disease. Inter-
nal target volume is defined as the envelope of all CTVs from 
the different respiratory phases and is used for treatment 
planning as the equivalent of the planning target volume for 
SBRT. In addition to the target volume, the entire liver, the re-
maining normal liver, both kidneys, the stomach, the duode-
num, and the spinal cord should be meticulously contoured 
and taken into consideration during SBRT planning. In addi-
tion to the dose constraint guidelines of the American Associ-
ation of Physicists in Medicine Task Group,21 the following ex-
plicit planning objectives should be defined when executing 
SBRT plans: 1) ≥700 mL of remaining normal liver should re-
ceive ≤15 Gy; 2) maximum dose (Dmax) to bowel, duodenum, 
and stomach, <24 Gy; 3) Dmax to spinal cord, <18 Gy; and 4) 
≥67% of each kidney should receive <15 Gy and V15 should be 
<35%. According to the 2014 Korean Liver Cancer Study 
Group guidelines,8 normal liver volume receiving a total dose 
of <15 Gy must be ≥700 mL, or the mean normal liver dose 
(liver minus GTV) must be limited to <28 Gy for liver SBRT.
Fig. 2. Different motion management methods in RT. (A) The motion-en-
compassing method refers to the covering of all possible positions of the 
moving tumor through the whole breathing cycle using 4D-CT images. 
Subsequently, a large volume of normal tissue may be irradiated. (B) The 
breath-hold method refers to let the patient hold breaths for a few sec-
onds under deep inspiration, and then deliver the radiation only when the 
liver is in a certain position. (C) The forced shallow breathing is a method 
of using a special external device such as an abdominal compressor to 
allow the patient to breathe shallow during radiation therapy. Although 
breath-hold and forced shallow breathing might result in patient discom-
fort or inconvenience during treatment, it can reduce the respiratory mo-
tion for liver tumors and enhance the accuracy. (D) The respiratory gating 
method is a method of turning on the radiation beam only during a specif-
ic respiratory cycle, after accurately grasping the position of a tumor ac-
cording to a patient‘s respiratory cycle in advance using 4D-CT images. 
(E) The real-time tracking method refers to tracking the movement of the 
tumor along the respiratory cycle using the surrogate on the abdominal 
surface or internal fiducial marker and then delivering the radiation fol-
lowing the tumor inside the body. No respiratory control and abdominal 
compression are needed. RT, radiotherapy; 4D, four-dimensional.
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CLINICAL OUTCOME OF STEREOTACTIC 
BODY RADIOTHERAPY FOR 
HEPATOCELLULAR CARCINOMA
Curative therapies can improve survival in early-stage HCC 
patients. Resection, percutaneous ethanol injection, and RFA 
have been considered effective local treatment options. How-
ever, when the effect of these treatments was limited due to 
the primary tumor location, RT can be considered as an alter-
native definitive or salvage treatment. Moreover, RT may be a 
feasible alternative for patients with inoperable tumors or 
who refuse surgery. In several prospective10,12-14,22-26 and retro-
spective11,27-37 papers, SBRT has been reported to be an effec-
tive, safe, and noninvasive treatment modality in newly diag-
nosed or recurrent cases when the position and size of the 
tumor are acceptable. In a recent meta-analysis,38 SBRT ex-
hibited an LC rate of 87% with tolerable acute toxicities of 
grade >3 (4.9%) in HCCs. 
Several prospective (phase I or II) trials that reported good 
outcomes of SBRT in HCCs have been conducted since 2001 
(Table 2). In 2010, Goodman, et al.24 conducted a phase I study 
in patients with HCC or metastatic liver tumors. Radiation 
doses were escalated from 18–30 Gy in 1 fraction, and the 
1-year LC rate was 77% with acceptable toxicity. The 2-year 
OS rate was 50% at a median follow-up of 17 months. Cardenes, 
et al.12 and Andolino, et al.13 performed prospective studies 
using 3–5-fraction SBRT in HCC patients with Child-Pugh 
class A or B disease. For Child-Pugh class A patients, 36–48 Gy 
in 3 fractions (dose-escalated) or 44 Gy in 3 fractions were 
used, while 40 Gy in 5 fractions were used for Child-Pugh 
class B patients. In all patients, the LC rate was higher than 
90%, and the 2-year OS rate was 60%. In 2012, a phase II Kore-
an study evaluated SBRT [median 57 Gy in 3 fractions (range, 
42–60 Gy)] in 47 patients with early-stage HCC.10 The 2-year 
LC and OS rates were 94.6% and 68.7%, respectively. SBRT 
was well tolerated with a Child-Pugh class increase from A to 
B only in 13% of patients after RT. In Canada, Bujold, et al.14 
reported phase I/II studies of 6-fraction SBRT in 102 Child-
Pugh class A patients with advanced HCC who were ineligible 
for standard locoregional therapies. The median tumor size 
was 7.2 cm, which was higher than reported by other groups, 
and 55% of patients had portal vein thrombosis. The pre-
scribed dose was 36 Gy in 6 fractions (range, 24–54 Gy), with 
the dose based on spared liver volume or other limiting nor-
mal tissues. After a median follow-up of 31 months, the 1-year 
LC rate was 87%, and median survival was 17 months. Out-
comes following SBRT for patients with liver dysfunction have 
also been prospectively assessed in 59 Child-Pugh class A-B9 
patients.26 The median volume of HCC was 33.6 cc, and 20% 
of participants had tumor thrombosis. The median OS of 
Child-Pugh class A and B patients was 45 and 17 months, re-
spectively, with estimated 2-year LC rates of 92% and 82%, re-
spectively. Four (11%) Child-Pugh class A patients and 8 Ta
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Child-Pugh class B patients (38%) experienced grade III/IV 
liver toxicity. For Child-Pugh class B patients (but not A), a 
dose to remained liver volume was associated with an in-
creased risk of toxicity.
Multiple retrospective studies have also reported excellent 
outcomes with SBRT for patients with HCCs (Table 3). Pub-
lished results of several retrospective studies have largely in-
cluded instances in which surgical resection or percutaneous 
ablative therapies were difficult, unfeasible, or rejected, as 
well as some pools of intermediate or advanced-stage HCC. 
Overall, promising outcomes with LC rates of 64–95% and OS 
rates of 43–87% at 2 years were reported. The wide variation in 
OS is due in part to different patient characteristics and the 
presence of tumor thrombosis in some series. 
Huang, et al.30 performed Cox multivariable regression haz-
ard analysis to compare OS curves of SBRT (n=36) and non-
SBRT (n=138) patient groups [hazard ratio (HR), 2.44; p=0.005] 
after adjustment for possible prognostic factors. The 2-year 
OS rates of SBRT recipients (n=28) and matched controls 
(n=28) (72.6% vs. 42.1%; p=0.013) were compared, concluding 
that SBRT significantly improved survival in patients with re-
current unresectable HCC. Honda, et al.32 showed that SBRT 
combined with TACE is an effective and safe locoregional 
treatment of small solitary primary HCC with a 96% complete 
response (CR) rate. In the largest series, Sanuki, et al.31 report-
ed on the outcomes of 185 patients with solitary HCCs ≤5 cm 
in size that were unsuitable for surgery or RFA. A total dose of 
40 Gy or 35 Gy in 5 fractions was prescribed for Child-Pugh 
class A and B patients, respectively. Three-year LC and OS 
rates were 91% and 70%, respectively, with no significant dif-
ference between dose levels. However, acute toxicity of ≥grade 
3 was observed in 13% of patients, occurring more frequently 
in Child-Pugh class B patients. Occasionally, SBRT was also 
used for tumor thrombosis in portal vein or inferior vena 
cava,39 Barcelona-Clinic Liver Cancer stage C HCC,35 Child-
Pugh class C patients,40 or large HCC ≥10 cm36,37,41 with accept-
able response rates and survival outcomes. Jang, et al.33 sug-
gested that there was a positive linear relationship between 
SBRT dose and 2-year LC and OS rates, which were highest at 
>54 Gy. As several clinical trials have demonstrated the effica-
cy and safety of SBRT, modern SBRT could provide an ablative 
dose to a tumor while sparing the remaining liver parenchyma.
SBRT as a curative treatment comparable to RFA 
According to the current guidelines of the European Associa-
tion for the Study of the Liver and the American Association 
for the Study of Liver Diseases,42,43 RFA is recommended as the 
first-line treatment for early-stage HCC. However, RFA has 
significant limitations, including size discrepancies, tumor 
proximity to major vascular or biliary structures, and limited 
accessibility on ultrasonography.44 Since RFA is based on the 
principle of frictional heat production by frequency waves, 
heat conduction rates decrease with increasing tumor size, 
resulting in inadequate tumor control. It is also well accepted 
that RFA of tumors in the liver dome is limited due to the in-
visibility under ultrasonography guidance. Several reports 
have described that either subphrenic location or a short dis-
tance from the diaphragm is associated with higher local re-
currence after RFA.45,46 Another study showed that approxi-
mately half of the tumors located in the liver dome recurred 
within 3 years after RFA due to inadequate ablation resulting 
from difficulties visualizing the tumor. SBRT can be a useful 
alternative in these situations. SBRT has a less strict indication 
for the size of tumors as discussed below. Furthermore, the 
therapeutic approach is not limited by tumor location when 
SBRT is implemented with daily IGRT. However, until now, 
little evidence has been available to determine the efficacy of 
SBRT compared to RFA. 
Recently, a noteworthy study has attracted widespread at-
tention from physicians due to the potential applications of 
SBRT and RFA. Wahl, et al.47 compared the outcomes of pa-
tients with nonmetastatic, inoperable HCCs who received 
SBRT or RFA. For tumors <2 cm, there was no significant dif-
ference between two treatments in freedom from local pro-
gression (FFLP) [HR, 2.50; 95% confidence interval (CI), 0.72 
to 8.67; p=0.15], but for tumors ≥2 cm, RFA was associated 
with a significantly worse FFLP (HR, 3.35; 95% CI, 1.17 to 9.62, 
p=0.025). More recently, an observational study analyzed a 
large cohort from the National Cancer Database to compare 
the effectiveness of RFA (n=3684) and SBRT (n=296) in pa-
tients with stage I or II HCC.48 This study demonstrated the 
opposite result. The 5-year OS rate was significantly higher in 
the RFA group [29.8% (95% CI, 24.5–35.3%)] than in the SBRT 
group [19.3% (95% CI, 13.5–25.9%)] (p<0.001) in both propen-
sity matching and probability-weighted analyses. The benefit 
of RFA was consistent across all subgroups and was robust to 
the effects of severe fibrosis or cirrhosis. However, this study 
may be limited by the biases related to its retrospective design 
although no other study with a similarly large cohort exists. A 
randomized clinical trial or more constructive studies would 
be helpful to confirm the results of these studies. A concerted 
effort should be made to identify a patient subgroup more 
suitable for RFA or SBRT shortly.
SBRT as a bridging treatment before liver 
transplantation
SBRT is also a suitable bridging therapy for patients with HCC 
awaiting LT. SBRT may enable patients with HCC to remain 
eligible for curative transplantation pending organ availabili-
ty.49,50 O’Connor, et al.50 demonstrated that successful ortho-
topic LT was undertaken following SBRT (median 6.3 months) 
in 10 patients with 11 HCCs. After the median follow-up of 62 
months, the median time from SBRT to LT was 113 days 
(range, 8–794 days). The 5-year OS and disease-free survival 
rates were both 100%, with only 4 of 10 patients experiencing 
acute toxicity. Explant pathology revealed a CR rate of 27% 
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while the remaining 8 tumors decreased or remained stable 
in size. In a recent paper by Sapisochin, et al.,51 379 patients 
who received LT after RFA (n=244), SBRT (n=36), or TACE 
(n=99) were compared to evaluate the efficacy and safety of 
bridging treatments. The drop-out and postoperative compli-
cation rates were similar between the groups. The 3-year sur-
vival from the time of transplant was 81% in the RFA group, 
75% in the SBRT group, and 75% in the TACE group, which 
was not significantly different. Theirs was the first study to 
show that SBRT may be as effective and safe as TACE or RFA 
when used to maintain the candidacy of patients with HCC 
on the transplant waiting list. 
A NEW ROLE FOR STEREOTACTIC 
BODY RADIOTHERAPY AS AN  
IMMUNOSTIMULATOR
Immunotherapy and HCC
Recent progress in the understanding of tumor biology and 
immune checkpoint has provided novel therapeutic strategies 
using immune checkpoint blockades. Over the years, different 
immunotherapeutic approaches have been evaluated for the 
treatment of HCC. Unlike certain other malignancies, HCC 
cells do not appear to be inherently immunogenic. However, 
recent papers that studied checkpoint inhibitors for HCC 
demonstrated promising results,52,53 and more phase I and II 
clinical studies are underway to investigate the effects of vari-
ous immune checkpoint inhibitors, including cytotoxic T-
lymphocyte-associated protein-4 inhibitors and anti-pro-
grammed death-1 (anti-PD-1) antibody. Nevertheless, 
modest response rates have indicated that the efficacy of 
these checkpoint inhibitors appears to be insufficient.54,55 
Therefore, the development of combination therapies appears 
to be necessary, which can not only provide direct tumoricid-
al effects but also enhance the antitumor effect of immuno-
therapy.
Recent preclinical studies had suggested that the effects of 
RT may be enhanced through the dissemination and activa-
tion of tumor-associated antigens when RT was delivered in 
combination with immunotherapeutic agents, especially in a 
high dose per fraction. One important mechanism that can 
explain this enhancement is the abscopal effect which means 
the treatment may affect even untreated areas.56 This strategy 
is particularly appealing, as conforming RT to a small target 
volume may enhance the efficacy of immunotherapy in HCC, 
leading to the eradication of untreated macroscopic lesions 
and/or occult microscopic disease. Consequently, RT elicited 
systemic anti-tumor effects mediated by the immune system. 
Preclinical data using human HCC tumor cultures and mu-
rine models demonstrated that RT increased cell surface ex-
pression of immunogenicity markers and increased sensitivity 
to dendritic cell therapy.57-59 Although further research is war-
ranted, several recent studies of the combination of RT and 
immunotherapy in the management of HCC have shown 
promising results.60-62 
SBRT as an immunostimulator 
Many preclinical studies demonstrated that high-dose per 
fraction RT has a beneficial outcome over classical RT frac-
tionation,63-65 even though some in vitro models suggested an 
advantage for classical fractionated RT.66-68 To identify the spe-
cific mechanism and confirm this hypothesis, Kim, et al.69 
published a preclinical study. Using the murine HCC cell line 
HCA-1, the effect of radiation (10 Gy per one fraction) on pro-
grammed death-ligand 1 (PD-L1) expression was measured. 
The signaling pathways involved in the altered PD-L1 expres-
sion, tumor growth, and survival rates were also evaluated. 
Radiation upregulated PD-L1 expression in tumor cells 
through interferon (IFN)-γ/signal transducer and activator of 
transcription 3 (STAT3) signaling, which could facilitate the 
therapeutic action of anti-PD-L1 in the murine HCC model. 
Furthermore, the combination of anti-PD-L1 and radiation 
significantly delayed tumor growth compared to treatment 
with anti-PD-L1 or radiation alone, enhancing survival signif-
icantly (7-week survival; 90% vs. 0% or 30%, respectively, 
p<0.001). The underlying mechanism involved increasing 
apoptosis, decreasing tumor cell proliferation, as well as the 
restoration of CD8+ T cell functions. 
The same group published another clinical study.70 The sol-
uble PD-L1 (sPD-L1) level was measured (before/after RT, 
and 1 month after RT) and compared between the SBRT group 
and the conventional RT group. The sPD-L1 level increased 
after RT but decreased after 1 month in patients who under-
went conventional RT, while it tended to increase continuous-
ly for 1 month in SBRT patients. These results suggest that 
SBRT may be superior to conventional fractionated RT for 
combined use with immune checkpoint inhibitors. Other 
well-designed studies of RT combined with immune check-
point inhibitors would be helpful to clarify the optimal RT 
scheme, dose, and time to implement the combination.
SBRT has been considered more immunogenic than con-
ventional fractionation.71,72 According to previous studies, sev-
eral possible mechanisms that act differently from those of 
conventional RT doses exist. First, although radiation-induced 
cell death is known to be caused predominantly by radiation-
induced DNA damage or breaks, radiation delivered at higher 
doses per fraction (8–10 Gy) may induce other more signifi-
cant vascular, stromal, and antitumor immune responses 
within the local tumor environment.73 Second, there is no 
danger signal when tumors are untreated, producing limited 
or tolerogenic antigen presentation. In contrast, upon receiv-
ing a tumoricidal dose of radiation, dying tumor cells release 
a large number of tumor antigens, and those antigens act as 
danger signals which actively induce the immunogenic re-
sponse. These tumor antigens also induce maturation of den-
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dritic cells and increase antigen presentation by these cells. 
These signals result in the activation and proliferation of tu-
mor-specific CD8 T cells. The release of danger signals from 
tumor cells appears to be more active by ablative dose per 1 
fraction than conventional dose per fraction. Third, radiation 
causes tumor cells to be more susceptible to immunogenic 
cell death. Radiation upregulates the major histocompatibility 
complex and first apoptosis signal receptor on tumor cells, in-
creasing their susceptibility to T cell-mediated cytotoxicity as 
well as increasing PD-L1 on tumor cells.74 Therefore, radiation 
combined with immune checkpoint inhibitors offer a more 
effective combination strategy than radiation alone. 
CONCLUSION
The use of SBRT for HCC appears to be a useful noninvasive 
option with an LC rate of approximately 90%. Numerous ad-
vances in EBRT allow for more accurate targeting and sparing 
of normal liver parenchyma, making aggressive dose-fraction-
ation strategies possible in daily practice. SBRT for HCC may 
be a curative treatment comparable to RFA as well as an effec-
tive bridging treatment before LT, although further multi-in-
stitutional prospective studies are warranted to confirm these 
results in the clinical setting. Moreover, a new role for SBRT as 
an immunostimulator is suggested by enhancing the antitu-
mor effect of immune checkpoint inhibitors in addition to its 
tumoricidal effect. 
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